Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NouvNeu001 in Parkinson's Disease
NCT07028632Phase 2Not yet recruiting
- Sponsor
- iRegene Therapeutics
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
A Phase 2 trial of NOUVNEU001 in Parkinson's disease (PD), sponsored by iRegene Therapeutics. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
NOUVNEU001
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07028632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028632.